Glecirasib

Glecirasib (JAB-21822) is a covalent KRAS G12C inhibitor developed by Jacobio Pharma that was approved in China in May 2025 for previously treated KRAS G12C-mutated NSCLC [1]. Its near-term catalyst is a Phase 3 trial (NCT06416410, n=392) testing glecirasib combined with sitneprotafib - a drug that blocks SHP2, a relay protein cancer cells use to bypass KRAS suppression - against standard-of-care chemoimmunotherapy in first-line NSCLC. That combination posted a 71% response rate in Phase 1/2a, though sotorasib and adagrasib have not been tested as frontline SHP2 combinations, making this a cross-line, cross-modality comparison rather than a direct benchmark [2]. The drug enters a market where the target is validated but the commercial ceiling remains modest - Amgen's sotorasib generated $350 million globally in 2024 [13] - and where Roche's divarasib is also advancing toward Phase 3. Note: the NCT ID in our database (NCT04793958) is a data error; that trial is KRYSTAL-10 for adagrasib, not glecirasib.

Glecirasib received NMPA approval in China on May 22, 2025, for adults with KRAS G12C-mutated NSCLC who progressed on at least one prior systemic therapy, making it the first KRAS G12C inhibitor approved in China [3]. In August 2024, Jacobio out-licensed exclusive China rights (mainland, Hong Kong, Macau, Taiwan) for glecirasib and sitneprotafib to Allist Pharmaceuticals under a structure where Allist commercializes both drugs and books China net product revenue, while Jacobio receives tiered double-digit royalties on net sales, an upfront payment of RMB 150 million, and development/regulatory/commercial milestones up to RMB 700 million [14]. Glecirasib's addition to China's National Reimbursement Drug List triggered a RMB 50 million milestone payment to Jacobio [3]. In China, glecirasib also holds a breakthrough therapy designation for KRAS G12C-mutated pancreatic cancer [4], with a Phase 2 trial (NCT06008288) recruiting 88 patients across pancreatic and other G12C-mutant solid tumors [5]. The Phase 3 first-line NSCLC combination trial (NCT06416410) comparing glecirasib plus sitneprotafib to tislelizumab (a PD-1 antibody) plus pemetrexed and carboplatin is actively enrolling with a target of 392 patients [10]. No US or EU regulatory filings have been made, and there is no FDA investigational new drug application publicly disclosed. Jacobio has not announced plans for a global registrational program, which limits the near-term commercial relevance outside China and positions this as primarily an Asia-focused asset for now.

KRAS is a protein that acts as an on/off switch for cell growth signaling. When a cell receives a growth signal, KRAS flips to its active (GTP-bound) state, tells the cell to divide, and then normally flips back off (GDP-bound). The G12C mutation - a single amino acid swap at position 12 - jams KRAS in the 'on' position, driving continuous cell proliferation. This mutation appears in roughly 13% of non-small cell lung cancers, 3-4% of colorectal cancers, and 1-2% of pancreatic cancers [6]. Glecirasib works by sneaking into a pocket on KRAS that is only accessible when the protein briefly cycles to its inactive GDP-bound state. The drug forms a permanent covalent bond with the mutant cysteine at position 12, trapping KRAS in the off position and shutting down the growth signal [7]. The mechanism is identical in principle to sotorasib and adagrasib. Where glecirasib gets interesting is the combination strategy. Tumors resist KRAS G12C inhibitors partly by reactivating upstream signaling through a protein called SHP2 - a molecular relay that feeds growth signals back into RAS. Jacobio developed sitneprotafib (JAB-3312) to block SHP2 specifically, cutting off this escape route. The dual blockade produced a 71% frontline ORR in a single-arm Phase 1/2a study, compared to ~37% for sotorasib as second-line monotherapy in CodeBreaK 100 - a cross-line, cross-modality comparison that overstates the direct therapeutic advantage [2][8].

The central trial to watch is NCT06416410: a randomized Phase 3 study of glecirasib plus sitneprotafib versus standard-of-care (tislelizumab plus pemetrexed plus carboplatin) in treatment-naive KRAS G12C-mutated NSCLC in China, enrolling an estimated 392 patients [10]. This trial represents the first Phase 3 test of a KRAS G12C inhibitor plus SHP2 inhibitor combination in any setting. The registrational Phase 2b monotherapy trial in second-line NSCLC (n=119) delivered the approval-enabling data: 47.9% ORR by independent central review, 8.2-month median PFS, 13.6-month median OS, and a duration of response where the median was not yet reached at data cutoff - 6-month and 12-month DoR rates were 73.6% and 56.6% respectively - at 800 mg daily dosing [1]. In CRC, two Phase 1/2 trials (JAB-21822-1002 and JAB-21822-1007) tested glecirasib alone and with cetuximab in previously treated KRAS G12C-mutant patients. The combination arm hit a 62.8% ORR (27/43 patients) versus 33.3% for monotherapy, with median PFS not yet reached for the combo at data cutoff [9]. A Phase 2 basket trial (NCT06008288) is recruiting 88 patients with pancreatic cancer and other KRAS G12C-mutant solid tumors [5]. The comparator choice in the Phase 3 (chemoimmunotherapy, not another KRAS inhibitor) is notable - it tests whether the all-oral KRAS/SHP2 combo can replace IV chemotherapy, which is a different question than showing superiority over existing KRAS drugs.

Our model puts the odds of this drug eventually getting approved at 75%. That estimate starts from a historical baseline of about 84% for drugs at this stage, then adjusts based on ten facts about the trial and the company behind it. The biggest positives are the trial's non-randomized design and its open-label setup; the biggest negatives are the sponsor's weak approval track record and limited earlier-phase results. The remaining factors are close to average, so they don't move the number much from where it started.

The most concrete safety concern is the combination toxicity profile. Glecirasib plus sitneprotafib caused grade 3-4 adverse events in 46% of patients, with anemia (61%), hypertriglyceridemia (60%), and elevated liver enzymes (49-56%) as the most frequent treatment-related events [2]. Only 2% discontinued treatment, which is manageable, but regulators will scrutinize whether this combination's benefit-risk profile beats chemoimmunotherapy in the first-line setting - a higher bar than beating chemotherapy alone. Commercially, the KRAS G12C inhibitor market is getting crowded. Sotorasib and adagrasib own the US and EU. Roche's divarasib posted a 53.4% ORR and 13.1-month PFS as monotherapy in NSCLC [11], and is likely headed for Phase 3. In China specifically, garsorasib (D-1553, InventisBio) holds NMPA fast-track designation and posted a pooled 48.1% ORR in KRAS G12C NSCLC across Phase 1/2, making it a direct regional competitor to glecirasib [15]. Even if glecirasib's combo data holds up in Phase 3, Jacobio has no disclosed path to US or EU regulatory filing. Without a major pharma partner for ex-China markets, the commercial opportunity is capped. A notable gap in glecirasib's profile is the absence of published CNS penetration or brain metastases data. Given that 25-40% of NSCLC patients develop brain metastases, this is a competitive disadvantage against adagrasib, which has demonstrated an intracranial ORR of 42% in KRAS G12C-mutant NSCLC [16]. Resistance is a class-wide issue: KRAS G12C inhibitors see acquired resistance through secondary KRAS mutations, bypass pathway activation, and histologic transformation. The SHP2 combination addresses one resistance mechanism but not all of them. The China-specific risk is pricing: inclusion in the National Reimbursement Drug List typically requires steep discounts that compress margins, and under the license structure Jacobio receives royalties rather than booking product revenue directly, limiting upside [14].

Glecirasib is worth tracking primarily for the Phase 3 combination readout (NCT06416410, n=392). If glecirasib plus sitneprotafib beats chemoimmunotherapy in first-line KRAS G12C NSCLC, it would be the first all-oral regimen to do so - a meaningful clinical advance and a commercial inflection point for Jacobio. The 71% frontline ORR from Phase 1/2a sets a high bar to maintain in a randomized trial against tislelizumab plus chemotherapy, and that readout will answer whether SHP2 dual blockade is genuinely superior or just a China-specific single-arm artifact. Check back when the Phase 3 interim analysis reads out, likely in late 2026 or 2027. The CRC combination data (62.8% ORR with cetuximab) also deserves attention as it benchmarks competitively with adagrasib plus cetuximab [9]. For investors, the deal structure matters: Allist books China product revenue while Jacobio receives royalties, so track Allist's commercial ramp as the leading indicator for Jacobio's P&L impact [14]. If the combo succeeds and Jacobio partners with a global pharma for US/EU rights, the asset profile changes fundamentally. Until then, glecirasib is a strong regional competitor with limited global reach.